{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:34:44Z","timestamp":1794360884334,"version":"4.9.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T00:00:00Z","timestamp":1510272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jhep.2017.10.010","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T18:50:50Z","timestamp":1515437450000},"page":"402-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"title":["Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe"],"prefix":"10.1016","volume":"68","author":[{"given":"Hannah","family":"Fraser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha K.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrikki","family":"Brummer-Korvenkontio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Dalgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jauffret-Roustide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00e5berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Matser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Mati\u010di\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havard","family":"Midgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Mravcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"\u00d8vrehus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Robaeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela K.","family":"van Santen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.10.010_b0005","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(14)61838-9","article-title":"Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis","volume":"384","author":"Williams","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.10.010_b0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.10.010_b0015","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2017.10.010_b0020","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0168-8278(14)60088-X","article-title":"O86 European responses in focus: comparing viral hepatitis and HIV related deaths in Europe 1990\u20132010 in the global burden of disease study 2010","volume":"1","author":"Cowie","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.10.010_b0025","series-title":"Prevention and control of infectious diseases among people who inject drugs","year":"2011"},{"key":"10.1016\/j.jhep.2017.10.010_b0030","series-title":"Hepatitis C among drug users in Europe: epidemiology, treatment and prevention. EMCDDA Insights, 23","year":"2016"},{"key":"10.1016\/j.jhep.2017.10.010_b0035","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/j.1360-0443.2011.03515.x","article-title":"The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence","volume":"106","author":"Turner","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.jhep.2017.10.010_b0040","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1360-0443.2007.01912.x","article-title":"Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users","volume":"102","author":"Van Den Berg","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.jhep.2017.10.010_b0045","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1360-0443.2012.03932.x","article-title":"Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings","volume":"107","author":"Vickerman","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.jhep.2017.10.010_b0050","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"Martin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2017.10.010_b0055","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jhep.2010.08.029","article-title":"Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility","volume":"54","author":"Martin","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.10.010_b0060","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.10.010_b0065","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/jvh.12249","article-title":"Strategies to manage hepatitis C virus (HCV) disease burden","volume":"21","author":"Wedemeyer","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.10.010_b0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mbs.2014.09.006","article-title":"Benefits of hepatitis C virus treatment: A balance of preventing onward transmission and re-infection","volume":"258","author":"De Vos","year":"2014","journal-title":"Math Biosci"},{"key":"10.1016\/j.jhep.2017.10.010_b0075","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/add.12125","article-title":"Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?","volume":"108","author":"de Vos","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.jhep.2017.10.010_b0080","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/cid\/civ197","article-title":"Hepatitis C virus therapeutic development: in pursuit of \u201cperfectovir\u201d","volume":"60","author":"Dore","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2017.10.010_b0085","doi-asserted-by":"crossref","unstructured":"G Everson, T Tran, W Towner, M Davis, D Wyles, R Nahass, et al. Safety and efficacy of treatment with the interferon-free ribavirin-free combination of sofosbuvir+ GS-5816 for 12 weeks in treatment naive patients with genotype 1\u20136 HCV infection. 49th European Association for the Study of the Liver International Liver Congress (EASL 2014). London, United Kingdom; 2014.","DOI":"10.1016\/S0168-8278(14)60113-6"},{"key":"10.1016\/j.jhep.2017.10.010_b0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jhep.2014.05.001","article-title":"EASL recommendations on treatment of hepatitis C 2014","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.10.010_b0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.10.010_b0105","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/hep.27736","article-title":"Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease","volume":"61","author":"Leidner","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.10.010_b0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","article-title":"Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation","volume":"65","author":"Martin","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.10.010_b0115","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/infdis\/jis213","article-title":"The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design","volume":"205","author":"Vickerman","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2017.10.010_b0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtbi.2010.12.041","article-title":"Mathematical modelling of hepatitis C treatment for injecting drug users","volume":"274","author":"Martin","year":"2011","journal-title":"J Theor Biol"},{"key":"10.1016\/j.jhep.2017.10.010_b0125","article-title":"Overall mortality of drug users in the Czech Republic","author":"Z\u00e1bransk\u00fd","year":"2009"},{"key":"10.1016\/j.jhep.2017.10.010_b0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000092117","article-title":"Hepatitis C virus infection among injecting drug users in the Czech Republic\u2013prevalence and associated factors","volume":"12","author":"Zabransky","year":"2006","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.jhep.2017.10.010_b0135","unstructured":"H \u0160v\u016fgerov\u00e1. Spot\u0159eba injek\u010dn\u00edho materi\u00e1lu klienty pra\u017esk\u00fdch harm reduction slu\u017eeb v z\u00e1vislosti na vzorc\u00edch u\u017e\u00edv\u00e1n\u00ed (Consumption of material for injection clients of Prague harm reduction services depending on use patterns): PhD Thesis, Clinic of Addictology of the 1st Faculty of Medicine and General Teaching Hospital in Prague (11\u201300611), Prague; 2015."},{"key":"10.1016\/j.jhep.2017.10.010_b0140","series-title":"Handbooks in Health Economic Evaluation Series","article-title":"Decision modelling for health economic evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.jhep.2017.10.010_b0145","series-title":"Hepatitis C surveillance in Europe \u2013 2013","year":"2015"},{"key":"10.1016\/j.jhep.2017.10.010_b0150","first-page":"kwu056","article-title":"Recapture or precapture? Fallibility of standard capture-recapture methods in the presence of referrals between sources","author":"Jones","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhep.2017.10.010_b0155","doi-asserted-by":"crossref","first-page":"e104515","DOI":"10.1371\/journal.pone.0104515","article-title":"Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions","volume":"9","author":"Palmateer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.10.010_b0160","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/cid\/ciw580","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2017.10.010_b0165","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir\u2013grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2017.10.010_b0170","doi-asserted-by":"crossref","first-page":"20141197","DOI":"10.1098\/rsif.2014.1197","article-title":"Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data","volume":"12","author":"Sacks-Davis","year":"2015","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.jhep.2017.10.010_b0175","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","article-title":"Protection against persistence of hepatitis C","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.10.010_b0180","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2017.10.010_b0185","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2893.2006.00812.x","article-title":"High incidence of hepatitis C virus reinfection within a cohort of injecting drug users","volume":"14","author":"Micallef","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.10.010_b0190","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/hep.22534","article-title":"High incidence of hepatitis C virus reinfection in a cohort of injecting drug users","volume":"48","author":"Aitken","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.10.010_b0195","first-page":"civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis","author":"Simmons","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2017.10.010_b0200","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.drugpo.2015.05.003","article-title":"Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C","volume":"26","author":"Alavi","year":"2015","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jhep.2017.10.010_b0205","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/00365521.2014.990505","article-title":"The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies","volume":"50","author":"Duberg","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.10.010_b0210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","article-title":"The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm","volume":"21","author":"Razavi","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.10.010_b0215","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jhep.2014.05.008","article-title":"Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenario","volume":"61","author":"Harris","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.10.010_b0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1371\/journal.pone.0125214","article-title":"Modeling the health and economic burden of hepatitis C virus in Switzerland","volume":"10","author":"Mullhaupt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.10.010_b0225","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/gutjnl-2014-308166","article-title":"Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?","volume":"64","author":"Innes","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.10.010_b0230","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jvh.12338","article-title":"HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact","volume":"22","author":"Martin","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.10.010_b0235","unstructured":"V Mrav\u010d\u00edk, C P., G K., N V., G L., K L., et al. V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2013 [Annual Report on Drug Situation 2013 \u2013 Czech Republic], MRAV\u010c\u00cdK V.2014, Praha: \u00da\u0159ad vl\u00e1dy \u010cesk\u00e9 republiky."},{"key":"10.1016\/j.jhep.2017.10.010_b0240","unstructured":"Reitox National Focal Point. Report on the drug situation 2013 of the republic of Slovenia, Drev A.2013, Ljubljana."},{"key":"10.1016\/j.jhep.2017.10.010_b0245","doi-asserted-by":"crossref","first-page":"e0163488","DOI":"10.1371\/journal.pone.0163488","article-title":"Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, the Netherlands","volume":"11","author":"van Santen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.10.010_b0250","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817323875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817323875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:15:30Z","timestamp":1570580130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817323875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0168827817323875"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.10.010","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}